
    
      This multicenter, randomized, open-labeled, positive controlled study is divided into two
      stages. The first one is aimed to exploit the optimal dose of Y-shape pegylated somatropin,
      while the second one is aimed to confirm the efficacy and safety of the study drug. A total
      of 400 prepubertal children with growth hormone deficiency were expected to enrolled.
      Subjects will firstly undergo a 52 weeks treatment, and then followed for 5 weeks.
    
  